Editorial Commentary: When Treating Cartilage Lesions With Osseous Involvement, Biologic 'Chondrofacilitation' Using Either Bone Marrow Aspirate Concentrate or Mesenchymal Stem Cells Augments Microfracture
| Autor: | Mathew Hamula, Bert R. Mandelbaum |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vascular Endothelial Growth Factor A
Pathology medicine.medical_specialty Biological Products Fractures Stress business.industry Cartilage Growth factor medicine.medical_treatment Mesenchymal stem cell Treatment options Mesenchymal Stem Cells Bone morphogenetic protein Vascular endothelial growth factor chemistry.chemical_compound Bone marrow aspirate medicine.anatomical_structure chemistry Bone Marrow Medicine Humans Orthopedics and Sports Medicine Surgical treatment business |
| Zdroj: | Arthroscopy : the journal of arthroscopicrelated surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 37(8) |
| ISSN: | 1526-3231 |
| Popis: | The use of biologic augmentation following microfracture for symptomatic cartilage defects of the knee with osseous involvement shows encouraging results. Bone marrow aspirate concentrate provides growth factors to the injury site, such as vascular endothelial growth factor, platelet-derived growth factor, transforming growth factor-βa, and bone morphogenetic proteins in addition to the mesenchymal stem cells present in the concentrate. Cellular-based therapies like mesenchymal stem cells are becoming more widely used in conjunction with surgical treatment of focal cartilage lesions with early promising results. Both treatment options improve clinical and radiographic outcomes. As for the efficacy of mesenchymal stem cells versus bone marrow aspirate concentrate, we believe that both have promising results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|